The Russian peptide bioregulator tradition — Khavinson and the St. Petersburg school

That question turned into a research program. The research program turned into an institution. And the institution — the St. Petersburg Institute of Bioregulation and Gerontology, which Khavinson has directed since its founding — has produced, over the span of five decades, one of the most unusual bodies of scientific work in the history of modern biology.

The conceptual frame that Khavinson and his colleague Vyacheslav Morozov proposed is deceptively simple. Every organ, they argued, contains short peptide signals — chains of two to four amino acids — that regulate tissue-specific gene expression and maintain homeostasis in that organ. These peptides don't circulate the way hormones do; they act locally, telling cells in the liver what genes a liver cell should be expressing, telling neurons in the cerebral cortex what genes a cortical neuron should be expressing, regulating the identity and function of each tissue type from the inside. As the body ages, the concentration of these regulatory peptides declines. The tissues begin to lose their precise functional identity. Gene expression drifts. Cells stop behaving like the specialized cells they're supposed to be and start behaving more generically, less efficiently, more susceptible to disorder.

The Khavinson-Morozov hypothesis followed from this: if you could identify the specific short peptides that regulate a given tissue, synthesize their active sequences in pure form, and administer them back to the body, you should be able to restore some of the homeostatic signaling the aging process has degraded. The body would, in effect, receive a reminder of what it is supposed to be doing.

This is a different model than the one Western pharmaceutical research runs on. Western drug development looks for molecules that block or activate specific receptors — targets with known functions where interference produces predictable downstream effects. The bioregulator model is more like providing the raw informational substrate for a system's own self-maintenance. Less wrench in the machinery, more sheet music for an orchestra that has started to lose the melody.

To test the hypothesis, Khavinson's team began extracting tissue preparations from animal organs. They took peptide-rich fractions from calf thymus glands. They took fractions from bovine cerebral cortex. They took fractions from pineal gland tissue, from cardiac muscle, from liver, from retina, from cartilage, from blood vessel walls. Each preparation was characterized for its peptide content and tested in animal models and, eventually, in human clinical use. The first-generation preparations were what pharmacologists would call polypeptide complexes — not pure single molecules, but mixtures of short regulatory peptides isolated from the source organ.

Thymalin was among the first. It is an extract from calf thymus, the gland central to T-cell development and immune function. The thymus involutes dramatically with age — the shrinkage is so consistent it's used as a biomarker of aging — and Thymalin was hypothesized to restore some of the thymic signaling lost in that involution. Studies showed effects on immune function markers, on lymphocyte activity, on various indicators of immune competence in aging subjects. Cortexin came from bovine cerebral cortex — a preparation of short peptides intended to support the same regulatory signaling in neural tissue that the cortical peptides provide in the intact brain. It has been used clinically in Russia since the 1980s for stroke recovery, traumatic brain injury, and pediatric neurodevelopmental conditions.

Then came the second generation: synthetic short peptides. Rather than working with tissue preparations, Khavinson's team identified the minimal active sequences within the peptide complexes — the two- to four-amino-acid chains that appeared to carry the regulatory signal — and synthesized them directly. This allowed a level of purity, characterization, and dosing precision that the extracts couldn't offer. Epitalon — a tetrapeptide (Ala-Glu-Asp-Gly) derived from the active fraction of the pineal extract Epithalamin — became one of the best-studied of these synthetic analogs. Research showed it could activate telomerase in human cells in culture, a finding striking enough that it was replicated independently and contributed to a significant body of work on Epitalon's geroprotective properties.

The full list of peptides that emerged from this tradition is remarkable in breadth. Pinealon (Glu-Asp-Arg) addresses the pineal gland and its age-related dysfunction. Cardiogen (Ala-Glu-Asp-Arg) is directed at cardiac tissue. Vesugen (Lys-Glu-Asp) targets blood vessel walls. Ovagen (Ile-Glu-Pro-Asp) is derived from liver and hepatic tissue fractions. Cartalax (Ala-Glu-Asp-Pro) targets cartilage and connective tissue. Livagen (Lys-Glu-Asp-Pro) is derived from liver extract. Cortagen (Ala-Glu-Asp-Pro) is directed at nerve tissue and cortical function. Each represents the same structural logic applied to a different organ system: extract the local regulatory signal, identify its minimal active sequence, synthesize it, and return it to the tissue from which it came.

The research program supporting these compounds spans more than fifty years, runs to thousands of published studies, and involves clinical populations numbering in the tens of thousands. In Russia, several of the first-generation preparations have been approved as medicines. Cortexin is prescribed by neurologists in Russia, Ukraine, and other CIS countries for the indications mentioned above. Thymalin is used in immunological contexts. The research has been serious, conducted by trained scientists, published in peer-reviewed journals, and refined over decades of clinical application.

Why, then, does virtually no practicing physician in the United States or Western Europe know these compounds exist?

The answer has several layers, and none of them is "the research is fraudulent." The studies are real. The problem is that they don't translate through the infrastructure Western medicine uses to evaluate evidence. The randomized controlled trial, as designed and regulated by the FDA and EMA, requires specific methodological standards — blinding protocols, statistical approaches, patient population definitions, outcome measure pre-registration — that the Russian literature often doesn't meet, not because the researchers were sloppy but because they were working within a different regulatory and scientific culture that defined rigor differently. The Russian clinical trial tradition relies more heavily on what it calls controlled clinical trials, which are often neither fully randomized nor blinded in the Western sense.

The language barrier compounded this. For most of the Soviet and early post-Soviet period, this work was published in Russian. It was simply not visible in the PubMed literature that Western researchers treat as the canon. Even today, a PubMed search for many of these peptides returns thin results — the English-language record is a fraction of the actual research base, which lives in Russian-language journals that most Western scientists have never accessed.

There is also the commercial problem. Western pharmaceutical development is driven by intellectual property. A compound that can be patented, manufactured at scale, and sold under market exclusivity is worth developing; a compound that cannot be patented in a commercially viable way attracts no investment from large pharmaceutical firms. Short peptides are difficult to patent in ways that create durable commercial exclusivity. The compounds in the Khavinson tradition are, in most cases, too short and too natural-seeming for broad patent protection. Without a commercial sponsor willing to fund the Western regulatory process — which costs hundreds of millions of dollars for a single compound — there is no pathway for these compounds to receive FDA review. The absence of FDA approval doesn't reflect a judgment that the evidence is insufficient; it reflects a judgment, made by commercial interests, that funding the review process wouldn't yield a return.

What the Khavinson tradition does contribute — honestly assessed — is substantial. The preclinical evidence across multiple organ systems is extensive, internally consistent, and mechanistically coherent. The clinical experience in Russia and CIS countries involves large numbers of patients with favorable safety profiles built up over decades of use. Several compounds have accumulated independent replication in Western preclinical work, including Epitalon. The telomerase-activation finding for Epitalon, in particular, has been replicated outside the original Russian context and is taken seriously in the biogerontology literature.

What it does not yet contribute, by Western evidentiary standards, is the kind of large, well-designed, placebo-controlled, pre-registered RCTs that would justify clinical recommendations in American or European medicine. That evidence gap is real. It may close as Western longevity researchers engage more seriously with this literature — and there are signs it is beginning to close. But for now, the honest account is this: a remarkable body of work, built over half a century by serious scientists, addressing mechanisms that are biologically plausible and in many cases empirically supported, remains largely outside Western clinical practice because the institutions that would validate it operate on different terms than the ones that produced it.

Khavinson himself has continued publishing into his 70s, contributing research to international journals, and the Institute has become more visible in longevity research circles as English translations of the literature have proliferated. The work is not hidden anymore. Whether it will be integrated into the evidence base that shapes clinical practice in the West is a different question — one that depends not just on the quality of the science but on the commercial and regulatory forces that decide what gets the full Western development process. The science earned its place at the table a long time ago.